On Apr. 9, 2020, Pfizer announced that the FDA had approved BRAFTOVIﾮ (encorafenib) in combination with cetuximab (marketed as ERBITUXﾮ) for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAFV600E mutation, as detected by an FDA-approved test, after prior therapy. The approval was based on results from the BEACON CRC trial, the only Phase 3 trial to specifically study patients with previously treated metastatic CRC with a BRAFV600E mutation.